Avid Bioservices Inc (CDMO)

[sunstar]

"Also of interest is the late-breaking abstract for Phase III data from Roche/Genetech's Atezolizumab versus docetaxel, which is being presented at ESMO a day earlier. For reference, here are the Phase II #'s
Overall survival in the intention-to-treat population was 12·6 months (95% CI 9·7–16·4) for atezolizumab versus 9·7 months (8·6–12·0) for docetaxel (hazard ratio [HR] 0·73 [95% CI 0·53–0·99]; p=0·04)."
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)00587-0.pdf

Bio, thanks for the NEJM and Lancet links. I note the ECOG 0 or 1, yielding 12.6 months OS, was a healthier body of patients compared to the SUNRISE trial. The treatment Response Rate was 19%.

"Eastern Cooperative Oncology Group performance status 0 or 1,"

"The response rate was 19% with nivolumab versus 12% with docetaxel (P=0.02). Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively)"
http://www.nejm.org/doi/full/10.1056/NEJMoa1507643#t=abstract


IMO

sunstar